精選著作 (Selected Publications)
轉譯醫學 (Translational Medicine)
I devote myself in clinical and translational research of multiple myeloma. We study the interaction between myeloma cells and stromal cells in bone marrow microenvironment of patients with multiple myeloma. I worked on a liquid biopsy project in which we demonstrated exosomal miRNA expression correlated to myeloma patients’ progression-free and overall survival. Our work was published on Blood journal in 2017. With the advances of the liquid biopsy, myeloma patients might be able to avoid bone marrow aspiration and biopsy to monitor treatment response and disease status.
-
Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, Roccaro AM, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial IM. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood. 2017 Apr; 129(17):2429-2436. (co-first author)
PubMed
-
Nassar AH, Mouw KW, Jegede O, Shinagare AB, Kim J, Liu CJ, Pomerantz M, Harshman LC, Van Allen EM, Wei XX, McGregor B, Choudhury AD, Preston MA, Dong F, Signoretti S, Lindeman NI, Bellmunt J, Choueiri TK, Sonpavde G, Kwiatkowski DJ. A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. British Journal of Cancer. 2020 Feb; 122(4):555-563.
PubMed
-
Mouhieddine TH, Sperling AS, Redd R, Park J, Leventha M, Gibson CJ, Manier S, Nassar AH, Capelletti M, Huynh D, Bustoros M, Sklavenitis-Pistofidis R, Tahri S, Hornburg K, Dumke H, Itani MM, Boehner CJ, Liu CJ, AlDubayan SH, Reardon B, Allen EMV, Keats JJ. Clonal Hematopoiesis Is Associated With Adverse Outcomes in Multiple Myeloma Patients Undergoing Transplant. Nature Communications. 2020 Jun; 11(1):2996.
PubMed
-
Zavidij O, Haradhvala NJ, Mouhieddine TH, Pistofidis RS, Cai S, Reidy M, Rahmat M, Flaifel A, Ferland B, Su NK, Agius MP, Park J, Manier S, Bustoros M, Huynh D, Capelletti M, Berrios B, Liu CJ, He MX, Braggio E, Fonseca R, Maruvka YE, Guerriero JL, Goldman M. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nature Cancer. 2020 Apr; 1:493-506.
PubMed
We have also been working on using cell-free DNA and CTCs to stratify myeloma patients into different risk groups. We found the tumor burden is correlated to the disease status and revised international staging system stages. Furthermore, I also participated in discovering the activation of the oncogenic translation and potential therapeutic inhibitors in multiple myeloma. I've been involved in sample collection, library preparation, and data analysis, contributing as a coauthor for the following work:
-
Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, Rhoades J, Liu CJ, Huynh D, Reed SC, Gydush G, Salem KZ, Rotem D, Freymond C, Yosef A, Perilla-Glen A, Garderet L, Van Allen EM, Kumar S, Love JC, Getz G, Adalsteinsson VA, Ghobrial IM. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nature Communications. 2018 Apr; 9(1):1691.
PubMed
-
Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, Ebright RY, Shi J, Park J, Glavey SV, Devine WG, Liu CJ, Leleu X, Quesnel B, Roche-Lestienne C, Snyder JK, Brown LE, Gray N, Bradner J, Whitesell L, Porco JA Jr, Ghobrial IM. Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Science Translational Medicine. 2017 May; 10;9(389):eaal2668.
PubMed
-
Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, Moschetta M, Mishima Y, Roccaro A, Detappe A, Liu CJ, Sacco A, Huynh D, Tai YT, Robbins MD, Azzi J, Ghobrial IM. Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. Molecular Cancer Therapeutics. 2018 Jul; 17(7):1454-1463.
PubMed
-
Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M, Liu CJ, Mishima Y, Kokubun K, Manier S, Salem KZ, Huynh D, Sacco A, Forward J, Roccaro AM, Battinelli EM, Ghobrial IM. Platelets Enhance Multiple Myeloma Progression via IL-1β Upregulation. Clinical Cancer Research. 2018 May; 24(10):2430-2439.
PubMed
-
Bouyssou JM, Liu CJ, Bustoros M, Sklavenitis-Pistofidis R, Aljawai Y, Manier S, Yosef A, Sacco A, Kokubun K, Tsukamoto S, Perilla Glen A, Huynh D, Castillo JJ, Treon SP, Leblond V, Hermine O, Roccaro AM, Ghobrial IM, Capelletti M. Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. PLoS One. 2018 Oct; 13(10):e0204589.
PubMed
-
Bustoros M, Kastritis E, Sklavenitis-Pistofidis R, Liu CJ, Hornburg K, Kanellias N, Kim G, Liu D, Gavriatopoulou M, Marinac CR, Roussou M, Migkou M, Noonan K, Reyes K, Rivotto B, Neuse CJ, Ziogas DC, Laubach J, Terpos E, Anderson KC, Richardson PG, Ghobrial IM. Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. American Journal of Hematology. 2019 May; 94(5):E146-E149.
PubMed
運算研究與大數據分析 (Computational Research)
Since 2015, I conducted delicately designed multivariable adjustment and matching across large cohort studies to ensure clinically comparable groups. By rigorously matching patients on age, sex, comorbidities, validated risk scores, and concomitant therapies, I minimized confounding by indication and strengthened causal inference. This carefully executed matching strategy underpins the robustness and internal validity of the findings across diverse populations, closely approximating randomized comparisons at a population level:
-
Chao TF, Liu CJ, Tuan TC, Chen SJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Chen TJ, Chiang CE, Chen SA. Rate-Control Treatment and Mortality in Atrial Fibrillation. Circulation. 2015 Oct; 132(17):1604-12. (co-first author)
PubMed
-
Chao TF, Liu CJ, Liao JN, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chen TJ, Lip GY, Chen SA. Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage. Circulation. 2016 Apr; 133(16):1540-7. (co-first author)
PubMed
-
Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen TJ, Lip GYH, Chen SA. Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study. Circulation. 2018 Jul; 138(1):37-47.
PubMed
I personally performed the RNA sequencing analysis in this study, a critical strength that enabled an unbiased, data-driven characterization of circulating exosomal miRNAs in multiple myeloma. This hands-on RNA-seq work directly informed the rational selection of biologically and clinically relevant miRNAs, forming the essential foundation for the subsequent custom TaqMan low-density array design. By anchoring targeted validation to my own sequencing results, the study ensured technical coherence, biological relevance, and strong translational rigor from discovery to clinical prognostic modeling. I designed a novel progression risk stratification algorithm using a proportional hazards–based scoring system that integrates bone marrow infiltration, serum IgM, β2-microglobulin, and albumin as continuous variables. This approach avoids arbitrary cutoffs and more accurately captures the biological continuum of asymptomatic Waldenström macroglobulinemia. The model robustly stratifies patients into low-, intermediate-, and high-risk groups with clearly distinct times to progression. Its validity and generalizability were confirmed through cross-validation, external international cohorts, and implementation as a web-based clinical tool for real-world use:
-
Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ. Progression risk stratification of Asymptomatic Waldenström Macroglobulinemia. Journal of Clinical Oncology. 2019 Jun; 37(16):1403-1411. (co-first author)
PubMed
Our team trained and implemented a novel deep learning–based framework to automatically delineate all major cardiac substructures and accurately calculate radiation dose distributions at a substructure level. This approach enabled comprehensive, high-throughput quantification of three-dimensional dose–volume parameters for each cardiac chamber and coronary artery, overcoming the limitations of conventional mean heart dose–based assessments. By integrating this model into a large contemporary cohort, the study established precise substructure-specific dose–risk relationships and identified clinically actionable dose constraints with direct relevance to modern radiotherapy planning:
-
Lai TY, Hu YW, Wang TH, Chen JP, Shiau CY, Huang PI, Lai IC, Tseng LM, Huang N, Liu CJ*. Association of Radiation Dose to Cardiac Substructures with Major Ischaemic Events Following Breast Cancer Radiotherapy. European Heart Journal. 2023 Dec; 44(45):4796-4807. (corresponding author)
PubMed
I developed a dedicated program to systematically extract patients’ computed tomography images from the clinical imaging system and enable precise measurement of vascular and external anatomic landmarks subsequently. This automated workflow allowed accurate, reproducible calculation of distances between body landmarks, forming the basis for robust morphometric analysis. By linking programmatic CT extraction with quantitative landmark measurements, the study provides a scalable and objective framework to optimize fluoroscopy-free REBOA catheter insertion in Taiwanese trauma patients:
-
Chien CY, Lee YL, Jeng MJ, Liu CJ*. Using Computed Tomography to Evaluate Anatomic Landmarks in Taiwanese Trauma Patients for Insertion of Resuscitative Endovascular Balloon Occlusion of the Aorta: A Retrospective Cohort Study. International Journal of Surgery. 2024 Sep; 110(12):7900-7908. (corresponding author)
PubMed
The following study, led by Dr. Kun-Hsing Yu, presents an uncertainty-aware ensemble framework that integrates multiple pathology foundation models. I participated in this international collaborative work, contributing to the multi-institutional effort that enabled rigorous validation on diverse FFPE and frozen-section slides. By explicitly modeling diagnostic uncertainty, the study substantially enhances reliability, generalizability, and clinical trustworthiness for real-world computational pathology applications:
-
Zhao J, Lin SY, Attias R, Mathews L, Engel C, Larghero G, Vremenko D, Kao TW, Lee TH, Wang YH, Tsai CC, Marostica E, Lo YC, Meredith D, Ligon KL, Arnaout O, Roetzer-Pejrimovsky T, Lin SC, Shih NN, Chaisuriya N, Cook DJ, Chiang JH, Liu CJ, Woehrer A, Golden JA, Nasrallah MP, Yu KH. Uncertainty-Aware Ensemble of Foundation Models Differentiates Glioblastoma from its Mimics – A Multi-Center Study. Nature Communications. 2025 Sep; 16(1):8341.
PubMed
癌症流行病學與臨床研究 (Cancer epidemiology)
-
Teng CJ, Hu YW, Chen SC, Yeh CM, Chiang HL, Chen TJ, Liu CJ*. Use of Radioactive Iodine for Thyroid Cancer and Risk of Second Primary Malignancy: A Nationwide Population-Based Study JNCI-Journal of the National Cancer Institute. 2015 Nov; 108(2):djv314. (corresponding author)
PubMed
-
Lai TY, Yeh CM, Hu YW, Liu CJ*. Hospital volume and physician volume in association with survival in patients with nasopharyngeal cancer after radiation therapy. Radiotherapy and Oncology. 2020 Oct; 151:190-199. (corresponding author)
PubMed
Important Publications on the Clinical Prognosis of Multiple Myeloma:
We have led the research team to investigate independent predictive factors for early mortality, fractures, infections, cerebrovascular events, and stem cell transplantation outcomes in patients with multiple myeloma. The findings have been published in the following journals:
-
Lee GY, Lee YT, Yeh CM, Hsu P, Lin TW, Gau JP, Yu YB, Hsiao LT, Tzeng CH, Chiou TJ, Liu JH, Liu YC, Liu CJ*. Risk of stroke in patients with newly diagnosed multiple myeloma: a retrospective cohort study. Hematological Oncology. 2017 Dec; 35(4):726-733. (corresponding author)
PubMed
-
Chen YL, Liu YC, Wu CH, Yeh CM, Chiu HI, Lee GY, Lee YT, Hsu P, Lin TW, Gau JP, Hsiao LT, Chiou TJ, Liu JH, Liu CJ*. Role of BMI and age in predicting pathologic vertebral fractures in newly diagnosed multiple myeloma patients: A retrospective cohort study. Hematological Oncology. 2018 Apr; 36(2):407-415. (corresponding author)
PubMed
-
Tsai CK, Liu YC, Kuan AS, Lee KL, Yeh CM, Lee YT, Hsiao LT, Ko PS, Wang HY, Chen PM, Liu JH, Hong YC, Liu CJ*, Gau JP. Risk and impact of invasive fungal infections in patients with multiple myeloma. Annals of Hematology. 2020 Aug; 99(8):1813-1822. (corresponding author)
PubMed
-
Tsai CK, Yeh CM, Hong YC, Chen PM, Liu JH, Gau JP, Liu CJ*. The influence of high-efficiency particulate air filtration on mortality among multiple myeloma patients receiving autologous stem cell transplantation. Scientific Reports. 2021 Jun; 11(1):11789. (corresponding author)
PubMed
-
Hsu TL, Tsai CK, Liu CY, Yeh CM, Lin FL, Hsiao LT, Liu YC, Wang HY, Ko PS, Lin TA, Chen WC, Chen PM, Liu JH, Gau JP, Liu CJ*. Risk Factors and Outcomes of Stem Cell Mobilization Failure in Multiple Myeloma Patients. Transfusion Medicine and Hemotherapy. 2022 Sep; 50(1):39-50. (corresponding author)
PubMed
-
Lin WY, Tsai CK, Yeh CM, Chian T, Liu YC, Wang HY, Ko PS, Lin TA, Hsiao LT, Chen PM, Gau JP, Liu CJ*. Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients. Cancer Medicine. 2023 Feb; 12(3):3013-3026. (corresponding author)
PubMed
-
Hsu TL, Tsai CK, Liu CY, Yeh CM, Lin FL, Hsiao LT, Liu YC, Chien SH, Wang HY, Ko PS, Lin TA, Chen WC, Chen PM, Liu JH, Gau JP, Liu CJ*. Risk Factors of Early Disease Progression and Decreased Survival for Multiple Myeloma Patients After Upfront Autologous Stem Cell Transplantation. Annals of Hematology. 2024 Mar; 103(8):2893-2904. (corresponding author)
PubMed
臨床試驗 (Clinical trials)
-
Laubach JP, Liu CJ, Raje NS, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Hedlund J, Martin MG, Reynolds CH, Shain K, Zackon I, Stampleman L, Henrick P, Rivotto BJ, Hornburg K, Dumke H, Chuma S, Savell A, Handisides D, Kroll S, Anderson KC, Richardson P. A Phase 1/2 Study of evofosfamide, A Hypoxia-Activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 2019 Jan; 25(2):478-486.
PubMed
-
Ghobrial IM, Liu CJ, Redd RA, Perez RP, Baz R, Zavidij O, Sklavenitis-Pistofidis R, Richardson PG, Anderson KC, Laubach J, Henrick P, Savell A, Reyes K, Hornburg K, Chuma S, Sabbatini P, Robbins MD, Becker PS. A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clinical Cancer Research. 2020 Jan 15; 26(2):344-353.
PubMed
-
Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. American Journal of Hematology. 2019 Nov; 94(11):1244-1253.
PubMed
其他重要研究 (Others)
-
Lai TY, Hu YW, Wang TH, Chen JP, Shiau CY, Huang PI, Lai IC, Liu YM, Huang CC, Tseng LM, Huang N, Liu CJ*. Estimating the risk of major adverse cardiac events following radiotherapy for left breast cancer using a modified generalized Lyman normal-tissue complication probability model. Breast. 2024 Oct; 77:103788. (corresponding author)
PubMed
-
Chang MC, Wu PF, Ho YC, Lin WY, Wu CY, Liu SY, Liu CJ*, Lin YT*. Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19, with or without severe renal impairment. Journal of Infection and Public Health. 2024 Jul; 17(7):102460. (co-corresponding author)
PubMed
